BCL2020 Ltd (t/a Biocleave)

Biocleave is a biotechnology company that developed an industrial platform specializing in the modification of non-pathogenic, solventogenic Clostridia for life-science applications. By engineering these microbes as recombinant protein expression hosts, the company aimed to overcome challenges related to host toxicity and production costs, allowing for the commercial-scale manufacture of difficult-to-express membrane-associated proteins and other biological reagents. The company's technology was designed to push boundaries in protein expression, making previously unobtainable reagents accessible for academic and industrial research in fields such as drug development and healthcare.

The company's work was particularly relevant for researchers and organizations requiring high-quality proteins for diagnostic testing and disease treatment development. By collaborating with academic institutions such as Aston University through knowledge transfer partnerships, Biocleave sought to refine its purification processes for challenging proteins. However, public records indicate that the entity BCL2020 Ltd (trading as Biocleave) entered into a creditors' voluntary liquidation in 2023.